Rosuvastatin Therapy in Prevention of Contrast-Induced Acute Kidney Injury in Patients with Chronic Kidney Disease

Authors

  • Asadullah, Bhagwan Das, Santosh Kumar, Abdul Manan Junejo, Rafia Memon, Om Lal

DOI:

https://doi.org/10.53350/pjmhs2023175216

Abstract

Objective: To determine the efficacy of rosuvastatin therapy in prevention of contrast-induced acute kidney injury in patients with chronic kidney disease.

Study design: Descriptive cross-sectional study.

Place and Duration of Study: Department of Nephrology, Jinnah Postgraduate Medical Centre (JPMC), Karachi, Pakistan from 21st January 2020 to 20th July 2019.

Methodology: One hundred and twenty-five patients were enrolled. Blood samples and creatinine levels were taken to measure CIN at 48 h and 72 h after PCI to assess the efficacy of therapy.

Results: The mean age was 51.1±10.6 years and mean duration of chronic kidney disease was 6.7±3.6 months. Seventy-eight (62.4%) were males while 47 (37.6%) were females. Efficacy of rosuvastatin therapy was found in 97 (77.6%) patients.

Conclusion: The efficacy of rosuvastatin therapy is an effective and safe treatment option in prevention of contrast induced acute kidney injury in patients with chronic renal failure.

Keywords: Efficacy, Rosuvastatin, Contrast induced nephropathy (CIN), Acute kidney injury, Chronic kidney disease

Downloads

How to Cite

Asadullah, Bhagwan Das, Santosh Kumar, Abdul Manan Junejo, Rafia Memon, Om Lal. (2023). Rosuvastatin Therapy in Prevention of Contrast-Induced Acute Kidney Injury in Patients with Chronic Kidney Disease. Pakistan Journal of Medical & Health Sciences, 17(05), 216. https://doi.org/10.53350/pjmhs2023175216